NEW YORK (GenomeWeb) – BioTheranostics today announced an agreement with DeNovo Sciences, a circulating tumor cell-based liquid biopsy company, to investigate the feasibility of using BioTheranostics’ proprietary biomarkers for blood-based cancer diagnostics.

According to BioTheranostics, the partners plan to perform proof-of-concept studies using DeNovo's Jetta CTC enrichment and single-cell analysis platform to enable the blood-based detection of undisclosed markers in BioTheranostics portfolio.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.

Sep
27
Sponsored by
Philips Genomics

This webinar will present an in-depth look at how Memorial Sloan Kettering Cancer Center has developed and implemented a next-generation sequencing panel for mutational tumor profiling of advanced cancer patients.

Oct
12
Sponsored by
PierianDx

This webinar will be a roundtable discussion on the adoption of a commercial gene panel for tumor profiling at several leading US cancer centers. 

Oct
17
Sponsored by
Cofactor Genomics

This webinar will discuss the benefits of genomically profiling the immune microenvironment of soft tissue sarcomas during neoadjuvant therapy.